ClinicalTrials.gg
CompletedNCT03719443Updated May 1, 2026Results posted

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

A Phase 1 interventional study of VIS649 and Placebo in Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy and IgA Nephropathy, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
39th of 67
51 · median 67
Started
2018
with 4 others
Phase 1
3 of 73
1 open now
Registered
21st of 73
by date
Lead sponsor
5 of 73
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 39th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2018, is one of 3 in phase 1, and was the 21st registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects.

VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.

The study will enroll up to 45 subjects and will be conducted in up to 5 sequential dosing cohorts at four different dose levels, enrolling 9 subjects per cohort. Subjects will be randomized to VIS649 or placebo in a ratio of 7:2 (7 active, 2 placebo). Safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from the initial cohorts will be assessed.

Read the detailed description

On Day 1, a single dose of VIS649 or placebo will be administered IV. Pharmacokinetics sampling will start with a collection prior to the start of infusion and at multiple timepoints throughout the study. Pharmacodynamics sampling will occur at baseline and multiple timepoints throughout the study.

Sentinel subjects will be utilized; the first two subjects in each cohort will be randomized to receive either VIS649 or placebo and will receive study drug at least 24 hours before the remaining subjects in the cohort are dosed.

The safety profile of these subjects over the 24 hour post-administration period will be reviewed to determine whether it is appropriate to proceed with enrollment of the remaining subjects in the cohort as planned. This will occur for each dose escalation.

The maximum duration of participation (Screening through End-of-study) for individual subjects will be approximately 20 weeks (5 months). The scheduled final visit will occur 16 weeks post-dosing (112 days).

03

Conditions studied

  • Immunoglobulin A Nephropathy
  • IgAN - IgA Nephropathy
  • IgA Nephropathy

Keywords

  • chronic glomerular disease
  • autoimmune glomerulonephritis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved form prior to performing any of the Screening Visit procedures and be able to sign and date an appropriate Health Insurance Portability and Accountability Act (HIPAA) authorization form or subject privacy form, if appropriate.
  2. Male and female subjects between 18 to 55 years of age, inclusive, at the Screening Visit.
  3. For Japanese subjects: Subject is of Japanese descent as evidenced by verbal confirmation of familial heritage (a subject has all four Japanese grandparents born in Japan).
  4. For non-Japanese subjects: Subjects must be of non-Asian descent, as evidenced by verbal confirmation that all four grandparents are non-Asian.
  5. The following applies to female subjects:

    • Non- (surgically sterile [hysterectomy or bilateral tubal ligation]) for at least 6 months, or ≥ 1 year, or
    • Non-pregnant, non-lactating females of childbearing potential must report prior use (over the 28 days prior to dosing of study drug) of medically acceptable forms of (hormonal contraception, abstinence, diaphragm with spermicide, condom with spermicide or intrauterine device, or partner with vasectomy), with agreement to continue to use a medically acceptable form of birth control (as described) through the end of their participation in the study. Alternatively, a reported history of abstinence beginning at least 28 days prior to study drug dosing, with agreement to continue abstinence through the end of their participation in the study are required. Females of childbearing potential must also have a negative serum human chorionic gonadotropin (hCG) pregnancy test at Screening and a negative urine hCG pregnancy test at Baseline (Day -1). Female subjects must also agree not to donate eggs/bank eggs for the duration of their participation in the study.
  6. For male, subject and/or his partner must use a highly effective form of contraception (i.e., double-barrier as described above, have had a vasectomy, or have a female partner of non childbearing potential) or agree to abstinence following study drug dosing, through the end of the subject's participation in the study. Male subjects must also agree to not donate sperm for the duration of their participation in the study, following study drug dosing.
  7. Screening laboratory values must meet the following criteria:

    • White blood cells 3,000 12,000/mm3
    • >150,000/mm3
    • >13 gm/dL for male and>11 gm/dL for female
    • Estimated >80 mL/min/1.73 m2
    • Serum creatinine \<1.25x (ULN)
    • Blood Urea Nitrogen (BUN) ≤25mg/dL
    • (AST) ≤50 U/L
    • Alanine aminotransferase (ALT) ≤67 U/L
    • Alkaline phosphatase ≤150 U/L
    • Total ≤1.4 mg/dL unless patient has Gilbert Syndrome, in which case direct bilirubin must be within normal range
    • Glucose (fasting) \<115 mg/dL
    • Drug and alcohol screen Negative
    • Serum Immunoglobulin G (IgG) >750 mg/dL (7.5 g/L)
    • Serum Immunoglobulin M (IgM) >55 mg/dL (0.55 g/L)
    • Serum IgA >80 mg/dL (0.8 g/L)
  8. (BMI) between 18 and 32 kg/m2, inclusive, at the Screening Visit.
  9. Healthy, determined by pre-study medical evaluation (medical history, physical examination, vital signs, 12-lead , and clinical laboratory evaluations), as judged by the Investigator.
  10. Is willing and able to comply with study restrictions and to remain at the central processing unit (CPU) for the in-patient duration of the study and return for all follow-up outpatient visits.
  11. or QTcB \< 450 msec at Screening (may be repeated once).

Exclusion criteria

Exclusion Criteria:

  1. Is participating in another clinical study of any drug, device, or intervention or has received any investigational medication during the last 30 days or five half-lives, whichever is longer, before Baseline (Day -1).
  2. Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study.
  3. Subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, , blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis or . History of minor skin cancers (not including melanoma) or surgically treated, limited cervical carcinomas (i.e., carcinoma in situ) are not exclusionary.
  4. Subject has a history or presence of proteinuria, chronic kidney disease, disease requiring therapy (including systemic ), or is considered to be immunosuppressed for any other reason.
  5. Previous receipt of antibody or biologic therapy whether licensed or investigational (immunoglobulin products, monoclonal antibodies or antibody fragments) within 30 days prior to dosing or 5 half-lives within the dose of Investigational medicinal products (IMP), whichever is longer.
  6. History of a previous severe allergic reaction with generalized urticaria; angioedema or anaphylaxis.
  7. Blood pressure >160/100 mmHg or \<90/50 mmHg (may be repeated once if abnormal), at the Screening visit and Day 1.
  8. Known hypoglobulinemia disorder (i.e., common variable immunodeficiency), X linked agammaglobulinemia, selective IgA deficiency, selective IgM deficiency).
  9. History of pre-existing latent infections (e.g., tuberculosis) or any infection requiring hospitalization or treatment with antivirals or antibiotics, or vaccination within 30 days prior to administration of study medication.
  10. Concomitant use of marketed or investigational systemic immunosuppressive or immunomodulatory medications (e.g., corticosteroids, methotrexate, azathioprine, etc. and/or biologics) is prohibited and require a prior to Screening (30 days or 5 half lives, whichever is longer).
  11. Has received any prescription or non-prescription (over-the-counter [OTC]) except acetaminophen or ibuprofen, including hormonal , topical medications, vitamins, dietary or herbal during the last 30 days or 5 half-lives, whichever is longer, preceding Baseline (Day -1).
  12. Subjects who consume more than 21 units of alcohol per week (7 days) or those who have a history of alcohol or drug/chemical abuse; one unit of alcohol is equivalent to eight ounces of beer, 4 ounces of wine, or one ounce of spirits.
  13. Subject is a user or former user of nicotine-containing products (including but not limited to cigarettes, cigars, and chewing or dipping tobacco) who stopped use or consumption (i.e., smoking, chewing, or pinching) of these nicotine-containing products less than 3 months before study drug administration or is using or has used topical or oral nicotine preparations for smoking cessation within the past 90 days before study drug administration.
  14. Subjects who consume greater than 500 mg of caffeine or xanthine-containing products per day (e.g., coffee, tea, soft drinks, energy drinks, or chocolate).
  15. Subjects who refuse to abstain from alcohol, xanthine-containing or caffeine-containing foods or beverages, or grapefruit foods or beverages, or Seville-orange containing foods (e.g., orange marmalade) or beverages, from 48 hours prior to check-in on Day-1 through the end of the study.
  16. Subjects with a positive urine drug (inclusive of marijuana) or alcohol Screening test result at Screening and Day -1.
  17. Subjects with a positive surface antigen test or evidence of chronic virus (HCV) infection at Screening (a negative HCV antibody assay at screening is sufficient to rule-out chronic HCV infection for this study).
  18. Subjects with a known history of a positive (HIV) or a positive test result at Screening.
  19. Subjects who have donated >500 mL or blood within 60 days prior to start of Screening.
  20. The subject has donated any plasma within 7 days prior to Baseline (Day -1).
  21. Is an employee of the clinical research team (any Visterra or research site employee), or has a family member who is an employee of these organizations.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    VIS649

    A single dose of VIS649 will be administered IV over approximately 1 hour on Day 1, at doses ranging from 0.5 mg/kg up to but not to exceed 20 mg/kg. No other doses will be administered during the study.

    Biological: VIS649

  • Placebo comparator
    Placebo

    Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.

    Biological: Placebo

Interventions

  • BiologicalVIS649

    Single IV dose of study product on Day 1 of study

  • BiologicalPlacebo

    Singe IV dose of placebo administered via IV on Day 1 of study

06

What researchers measure

Primary outcomes

  1. Overall Summary of Treatment Emergent Adverse Events

    The number adverse events (AEs), serious adverse events (SAEs), and drug related events following administration of VIS649. Safety will be assessed via AE severity per CTCAE v4.0

    Time frame: Baseline to day 112

Secondary outcomes

  1. Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants

    The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  2. Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participant

    The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  3. The Pharmacokinetic Exposure Profiles of VIS649 in Serum. All Participants

    Summary of the pharmacokinetic profiles of VIS649 exposure in serum for all participants. AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  4. T 1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants

    The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  5. CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose.

    The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants.

    Time frame: Day 1 to day 112

  6. Vd: The Volume of Distribution of VIS649 in Serum Samples. All Participants

    The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants.

    Time frame: Day 1 to day 112

  7. Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Time Profile. Japanese Participants

    The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Japanese participants

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  8. Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Japanese Participants

    The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Japanese participants.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  9. The Pharmacokinetic Exposure Profiles of VIS649 in Serum. Japanese Participants

    AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  10. T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Japanese Participants

    The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  11. CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Japanese Participants

    The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

    Time frame: Day 1 to day 112.

  12. Vd: The Volume of Distribution of VIS649 in Serum Samples. Japanese Participants

    The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

    Time frame: Day 1 to day 112.

  13. Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants

    The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  14. Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants

    The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  15. The Pharmacokinetic Exposure Profiles of VIS649 in Serum. Non-Japanese Participants

    Summary of the pharmacokinetic profiles of VIS649 exposure in serum for non-Japanese participants. AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  16. T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Non-Japanese Participants

    The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Non-Japanese participants.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  17. CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Non-Japanese Participants

    The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

    Time frame: Day 1 to day 112.

  18. Vd: The Volume of Distribution of VIS649 in Serum Samples. Non-Japanese Participants

    The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

    Time frame: Day 1 to day 112.

  19. Pharmacodynamic Effect of VIS649 on Total Immunoglobulin G Species. All Participants

    The effect of VIS649 treatment on total IgG levels in serum, weekly observations from baseline to Week 24

    Time frame: From baseline to Week 24

  20. Pharmacodynamic Effect of VIS649 on Total Immunoglobulin A Species. All Participants

    The effect of VIS649 treatment on total IgA levels in serum, weekly observations from Baseline to Week 24

    Time frame: From baseline to Week 24

  21. Pharmacodynamic Effect of VIS649 on Total Immunoglobulin M Species. All Participants

    The effect of VIS649 treatment on total IgM levels in serum, weekly observations from Baseline to Week 24

    Time frame: From baseline to Week 24

  22. Pharmacodynamic Effect of VIS649 on Circulating CD16 +CD56 (Natural Killer) Cells for All Participants in Cohorts 1-4

    The effect of VIS649 treatment on the population of circulating CD16 +CD56 (Natural killer) cells in serum for all participants in cohorts 1-4.

    Time frame: From baseline to Week 24

  23. Pharmacodynamic Effect of VIS649 on Circulating CD19 (B Cells) for All Participants in Cohorts 1-4

    The effect of VIS649 treatment on the population of circulating CD19 (B Cells) in serum for all participants in cohorts 1-4.

    Time frame: From baseline to Week 24

  24. Pharmacodynamic Effect of VIS649 on Circulating CD4 T Cells for All Participants in Cohorts 1-4

    The effect of VIS649 treatment on the population of circulating CD4 T cells in serum for all participants in cohorts 1-4.

    Time frame: From baseline to Week 24

  25. Pharmacodynamic Effect of VIS649 on Circulating CD3 T Cells for All Participants in Cohorts 1-4

    The effect of VIS649 treatment on the population of circulating CD3 T cells in serum for all participants in cohorts 1-4.

    Time frame: From baseline to Week 24

  26. Pharmacodynamic Effect of VIS649 on Circulating CD8 T Cells for All Participants in Cohorts 1-4

    The effect of VIS649 treatment on the population of circulating CD8 T cells in serum for all participants in cohorts 1-4.

    Time frame: From baseline to Week 24

  27. Summary of Anti -VIS649 Anti-drug Antibodies (ADA)

    Summary of Anti -VIS649 anti-drug antibodies (ADA) by treatment group, all participants

    Time frame: Baseline to Day 112

  28. Summary of Anti -VIS649 Antibody (ADA) Titer by Treatment

    Summary of Anti -VIS649 antibody (ADA) titer by treatment, all participants with ADA positive results

    Time frame: Baseline to Day 112

  29. Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants by Anti-VIS649 Status

    The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 status (positive or negative).

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  30. Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants by Anti-VIS649 Status

    The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 status (positive or negative).

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  31. The Pharmacokinetic Exposure Profiles of VIS649 in Serum Samples, All Participants by Anti-VIS649 Antibody Status.

    Summary of the pharmacokinetic profiles of VIS649 exposure in serum for all participants based on their anti-VIS649 antibody status (negative/positive). AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  32. T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants by Anti-VIS649 Antibody Status.

    The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (negative/positive).

    Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.

  33. CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. All Participants by Anti-VIS649 Antibody Status.

    The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (positive or negative)..

    Time frame: 112 days

  34. Vd: The Volume of Distribution of VIS649 in Serum Samples. All Participants by Anti-VIS649 Antibody Status (Positive or Negative)

    The calculated volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (positive or negative).

    Time frame: 112 days

07

Results

Posted Mar 20, 2025

Participant flow

Recruitment was done for a single clinical site.

Participant flow — Overall Study
MilestonePooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + Vaccine
Started87777510
Completed8757659
Not completed0020101
Withdrew: Lost to follow-up0010101
Withdrew: Withdrawal by subject0010000

Outcome measures

PrimaryOverall Summary of Treatment Emergent Adverse Events

The number adverse events (AEs), serious adverse events (SAEs), and drug related events following administration of VIS649. Safety will be assessed via AE severity per CTCAE v4.0

Time frame:
Baseline to day 112
Reported as:
Number · Event
Overall Summary of Treatment Emergent Adverse Events
EventPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + Vaccine
Adverse Events8377764
Serious Adverse Events0000000
Drug related events3233110
Mild severity4221334
Moderate severity0002000
Severe severity0010000
SecondaryCmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants

The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · μg/mL
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants
μg/mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants12.600 ± 2.22248.600 ± 11.660135.900 ± 20.380282.600 ± 48.440130.700 ± 20.150
SecondaryTmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participant

The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Median · hours
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participant
hoursVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participant1.136 (1.12 to 3.11)3.045 (1.15 to 3.09)3.038 (1.13 to 3.16)1.148 (1.11 to 9.11)3.053 (1.14 to 25.11)
SecondaryThe Pharmacokinetic Exposure Profiles of VIS649 in Serum. All Participants

Summary of the pharmacokinetic profiles of VIS649 exposure in serum for all participants. AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · h*μg/mL
The Pharmacokinetic Exposure Profiles of VIS649 in Serum. All Participants
h*μg/mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
AUC 0-112 days1118 ± 209.411680 ± 340274500 ± 18570176300 ± 2610057900 ± 18390
AUC 0-last885.2 ± 146.210510 ± 281172760 ± 19210148900 ± 1746053630 ± 18180
AUC 0-inf1118 ± 209.511670 ± 340374380 ± 18620187400 ± 3598057910 ± 18390
SecondaryT 1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants

The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · hours
T 1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants
hoursVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
T 1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants60.72 ± 4.35175.20 ± 38.40230.90 ± 76.20670 ± 179.80342.10 ± 91.62
SecondaryCL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose.

The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants.

Time frame:
Day 1 to day 112
Reported as:
Mean · mL/h
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose.
mL/hVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose.31.46 ± 4.54411.70 ± 2.5226.125 ± 2.2634.508 ± 1.3758.724 ± 4.137
SecondaryVd: The Volume of Distribution of VIS649 in Serum Samples. All Participants

The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants.

Time frame:
Day 1 to day 112
Reported as:
Mean · mL
Vd: The Volume of Distribution of VIS649 in Serum Samples. All Participants
mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
Vd: The Volume of Distribution of VIS649 in Serum Samples. All Participants2747 ± 351.62854 ± 323.52183 ± 13654122 ± 780.43911 ± 828.4
SecondaryCmax: Maximum Serum VIS649 Concentration Determined Directly From the Time Profile. Japanese Participants

The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Japanese participants

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · μg/mL
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Time Profile. Japanese Participants
μg/mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Time Profile. Japanese Participants11.83 ± 1.17240.13 ± 4.302133.0 ± 12.12249.0 ± 47.84
SecondaryTmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Japanese Participants

The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Japanese participants.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Median · hours
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Japanese Participants
hoursVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Japanese Participants1.136 (1.13 to 3.05)3.045 (1.15 to 3.09)3.049 (1.14 to 3.16)3.064 (1.12 to 9.11)
SecondaryThe Pharmacokinetic Exposure Profiles of VIS649 in Serum. Japanese Participants

AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · h*μg/mL
The Pharmacokinetic Exposure Profiles of VIS649 in Serum. Japanese Participants
h*μg/mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
AUC 0-112 days1039 ± 56.059405 ± 434.587210 ± 11210185200 ± 32550
AUC 0-last820.6 ± 25.488824 ± 216.385750 ± 11220150300 ± 21630
AUC 0-inf1039 ± 56.019399 ± 432.187170 ± 11210203500 ± 47430
SecondaryT1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Japanese Participants

The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · hours
T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Japanese Participants
hoursVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Japanese Participants59.24 ± 3.623158.8 ± 14.67189.8 ± 12.65778.4 ± 247.3
SecondaryCL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Japanese Participants

The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

Time frame:
Day 1 to day 112.
Reported as:
Mean · mL/h
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Japanese Participants
mL/hVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Japanese Participants28.58 ± 1.79412.26 ± 0.76514.385 ± 1.2423.618 ± 1.442
SecondaryVd: The Volume of Distribution of VIS649 in Serum Samples. Japanese Participants

The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

Time frame:
Day 1 to day 112.
Reported as:
Mean · mL
Vd: The Volume of Distribution of VIS649 in Serum Samples. Japanese Participants
mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
Vd: The Volume of Distribution of VIS649 in Serum Samples. Japanese Participants2441 ± 197.92816 ± 390.31197 ± 344.53772 ± 674.7
SecondaryCmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants

The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · μg/mL
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants
μg/mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants13.18 ± 2.81654.95 ± 11.57138.1 ± 26.80307.8 ± 34.56130.7 ± 20.15
SecondaryTmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants

The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Median · hours
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants
hoursVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants1.170 (1.12 to 3.11)2.253 (1.18 to 3.09)2.159 (1.13 to 3.06)1.142 (1.11 to 3.09)3.053 (1.14 to 25.11)
SecondaryThe Pharmacokinetic Exposure Profiles of VIS649 in Serum. Non-Japanese Participants

Summary of the pharmacokinetic profiles of VIS649 exposure in serum for non-Japanese participants. AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · h*μg/mL
The Pharmacokinetic Exposure Profiles of VIS649 in Serum. Non-Japanese Participants
h*μg/mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5
AUC 0-112 days1177 ± 273.413380 ± 374164960 ± 17990169700 ± 2279057900 ± 18390
AUC 0-last933.6 ± 187.111780 ± 328363020 ± 18950147900 ± 1716053630 ± 18180
AUC 0-inf1177 ± 273.613380 ± 374164790 ± 17980175300 ± 2520057910 ± 18390
SecondaryT1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Non-Japanese Participants

The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Non-Japanese participants.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · hours
T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Non-Japanese Participants
hoursVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Non-Japanese Participants61.83 ± 5.017187.6 ± 48.26261.8 ± 92.45588.8 ± 57.65342.1 ± 91.62
SecondaryCL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Non-Japanese Participants

The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

Time frame:
Day 1 to day 112.
Reported as:
Mean · mL/h
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Non-Japanese Participants
mL/hVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Non-Japanese Participants33.63 ± 4.95911.27 ± 3.4317.430 ± 1.9785.175 ± 1.0048.724 ± 4.137
SecondaryVd: The Volume of Distribution of VIS649 in Serum Samples. Non-Japanese Participants

The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.

Time frame:
Day 1 to day 112.
Reported as:
Mean · mL
Vd: The Volume of Distribution of VIS649 in Serum Samples. Non-Japanese Participants
mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5
Vd: The Volume of Distribution of VIS649 in Serum Samples. Non-Japanese Participants2976 ± 241.02882 ± 324.32923 ± 13954384 ± 8373911 ± 828.4
SecondaryPharmacodynamic Effect of VIS649 on Total Immunoglobulin G Species. All Participants

The effect of VIS649 treatment on total IgG levels in serum, weekly observations from baseline to Week 24

Time frame:
From baseline to Week 24
Reported as:
Median · mg/dL
Pharmacodynamic Effect of VIS649 on Total Immunoglobulin G Species. All Participants
mg/dLPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + Vaccine
Baseline1138.0 ± 288.081057 ± 276.81243 ± 293.551239.0 ± 269.731125.0 ± 262.831080.0 ± 225.921143.0 ± 213.59
Week 11152.0 ± 323.581028.0 ± 257.121140.0 ± 212.101142.0 ± 246.841174.0 ± 298.251098.0 ± 225.061092.5 ± 263.15
Week 21150.5 ± 280.89987.0 ± 271.891120.0 ± 220.631108.0 ± 196.161038.0 ± 240.461117.0 ± 201.081053.5 ± 216.66
Week 31174.0 ± 293.55946.0 ± 242.331077.0 ± 214.351076 ± 214.49999.0 ± 212.581063.0 ± 202.43966.5 ± 235.63
Week 41184.0 ± 304.931122.0 ± 264.191038.0 ± 218.351053.0 ± 196.391034 ± 221.081077.0 ± 186.741050.0 ± 204.29
Week 51143.5 ± 237.34994.0 ± 276.89965.0 ± 193.191005.0 ± 216.24980.0 ± 184.591094.0 ± 180.03962.0 ± 197.14
Week 61185.5 ± 295.651105.0 ± 285.27990.0 ± 216.581001.0 ± 212.64850.0 ± 191.401111.0 ± 202.60971.0 ± 194.19
Week 71195.0 ± 296.0950.5 ± 320.911005.0 ± 236.55948.0 ± 195.02929.0 ± 184.67——
Week 81199.5 ± 311.201022.0 ± 287.471022.5 ± 220.65974.0 ± 174.83951.5 ± 222.491117.0 ± 223.8953.0 ± 192.19
Week 101266.0 ± 301.041035.0 ± 333.11985.0 ± 234.141006.0 ± 223.84841.0 ± 196.811037.0 ± 196.39845.0 ± 211.71
Week 121215.0 ± 282.42992.0 ± 287.941036.0 ± 238.291027.0 ± 168.63718.0 ± 185.801101.0 ± 205.66970.0 ± 256.28
Week 141180.0 ± 282.871038.0 ± 278.83930.0 ± 268.001071.5 ± 160.55862.0 ± 180.07——
Week 161147.5 ± 278.041072.0 ± 242.20934.0 ± 356.271104.0 ± 233.23876.0 ± 220.381198.0 ± 156.101049.0 ± 261.94
Week 201269.0 ± 279.38——1089.0 ± 260.551009.0 ± 243.52——
Week 241250.5 ± 312.89——1075.0 ± 260.55917.5 ± 91.00——
SecondaryPharmacodynamic Effect of VIS649 on Total Immunoglobulin A Species. All Participants

The effect of VIS649 treatment on total IgA levels in serum, weekly observations from Baseline to Week 24

Time frame:
From baseline to Week 24
Reported as:
Median · mg/dL
Pharmacodynamic Effect of VIS649 on Total Immunoglobulin A Species. All Participants
mg/dLPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + Vaccine
Baseline217.0 ± 70.44202.0 ± 71.69213.0 ± 82.89233.0 ± 136.30243.0 ± 96.48202.0 ± 77.00222.5 ± 65.16
Week 1225.0 ± 68.74165.0 ± 64.10223.0 ± 64.03209.0 ± 120.23214.0 ± 100.42198.0 ± 84.45205.5 ± 57.03
Week 2222.5 ± 74.97151.0 ± 60.23168.0 ± 52.76187.0 ± 111.5174.0 ± 82.09205.0 ± 83.70179.0 ± 48.79
Week 3217.0 ± 73.17147.0 ± 54.07158.0 ± 49.15163.0 ± 103.95155.0 ± 74.91193.0 ± 84.93155.5 ± 41.48
Week 4227.0 ± 76.14169.0 ± 75.99134.0 ± 48.87152.0 ± 87.08146.0 ± 73.05197.0 ± 81.96150.0 ± 42.75
Week 5208.5 ± 71.81164.0 ± 64.44133.0 ± 43.46142.0 ± 87.7128.0 ± 60.93194.0 ± 87.73137.0 ± 38.30
Week 6217.5 ± 71.98167.0 ± 67.82140.0 ± 51.43134.0 ± 76.69116.0 ± 66.61207.0 ± 90.44129.0 ± 37.00
Week 7229.0 ± 68.86152.5 ± 71.68148.0 ± 53.76113.0 ± 74.53110.5 ± 68.99——
Week 8217.0 ± 68.26159.5 ± 74.21148.5 ± 59.02109.0 ± 68.40111.0 ± 66.42210.0 ± 92.31122.0 ± 35.26
Week 10215.5 ± 67.79161.0 ± 59.74171.0 ± 60.80123.0 ± 89.55105.0 ± 61.87207.0 ± 83.97127.0 ± 46.87
Week 12227.5 ± 74.44169.0 ± 65.26171.0 ± 59.46179.0 ± 107.2087.0 ± 59.27192.0 ± 85.87144.0 ± 54.34
Week 14232.0 ± 69.85182.0 ± 70.26164.0 ± 63.82195.5 ± 105.85109.0 ± 56.66——
Week 16220.0 ± 70.88179.0 ± 69.35165.0 ± 89.38158.0 ± 116.54124.0 ± 71.96192.0 ± 85.98169.0 ± 52.57
Week 20243.5 ± 90.16——172.0 ± 117.30153.0 ± 67.43——
Week 24239.0 ± 94.36——164.0 ± 123.92153.5 ± 83.43——
SecondaryPharmacodynamic Effect of VIS649 on Total Immunoglobulin M Species. All Participants

The effect of VIS649 treatment on total IgM levels in serum, weekly observations from Baseline to Week 24

Time frame:
From baseline to Week 24
Reported as:
Median · mg/dL
Pharmacodynamic Effect of VIS649 on Total Immunoglobulin M Species. All Participants
mg/dLPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + Vaccine
Baseline105.0 ± 43.75116.0 ± 42.7793.0 ± 61.79108.0 ± 49.11133.0 ± 31.6785.0 ± 35.75132.0 ± 34.80
Week 1108.0 ± 38.78117.0 ± 39.9170.0 ± 46.31100.0 ± 46.15128.0 ± 28.8085.0 ± 36.02102.5 ± 31.82
Week 2109.5 ± 42.3991.0 ± 39.0458.0 ± 38.1788.0 ± 43.6894.0 ± 29.8987.0 ± 30.8687.0 ± 25.15
Week 3105.0 ± 39.4985.0 ± 34.4952.0 ± 35.4071.0 ± 38.1780.0 ± 26.1386.0 ± 38.9173.5 ± 24.02
Week 4107.5 ± 43.1384.0 ± 40.4546.0 ± 31.0858.0 ± 34.9575.0 ± 25.3281.0 ± 35.9168.0 ± 20.35
Week 5106.0 ± 39.4183.0 ± 34.5440.5 ± 23.0149.0 ± 32.1360.0 ± 19.8584.0 ± 35.5054.0 ± 15.41
Week 6106.5 ± 42.1092.0 ± 37.2146.0 ± 30.3349 ± 30.3557.0 ± 21.0790 ± 35.2248.0 ± 13.30
Week 7109.5 ± 44.4186.5 ± 35.0748.0 ± 31.1443.0 ± 23.8851.5 ± 18.5——
Week 8110.5 ± 40.7389.5 ± 37.9143.0 ± 26.7746.0 ± 23.8046.0 ± 19.3189.0 ± 33.9342.0 ± 11.07
Week 10104.5 ± 40.87106.0 ± 40.4453.0 ± 29.9549.0 ± 25.1544.0 ± 18.0980.0 ± 32.3849.0 ± 19.53
Week 12113.0 ± 41.39106.0 ± 37.8954.0 ± 36.4173.5 ± 26.4635.0 ± 20.3093.0 ± 41.3763.0 ± 25.09
Week 14113.0 ± 40.09114.0 ± 41.3255.0 ± 33.0582.5 ± 30.3144.0 ± 15.14——
Week 16107.0 ± 40.51127.0 ± 40.5160.0 ± 30.7078.0 ± 39.5255.0 ± 24.0893.0 ± 31.1187.0 ± 30.55
Week 2080.0 ± 42.54——90.0 ± 38.1169.0 ± 23.84——
Week 2489.0 ± 33.56——89.0 ± 40.1574.5 ± 21.08——
SecondaryPharmacodynamic Effect of VIS649 on Circulating CD16 +CD56 (Natural Killer) Cells for All Participants in Cohorts 1-4

The effect of VIS649 treatment on the population of circulating CD16 +CD56 (Natural killer) cells in serum for all participants in cohorts 1-4.

Time frame:
From baseline to Week 24
Reported as:
Median · cells/mcl
Pharmacodynamic Effect of VIS649 on Circulating CD16 +CD56 (Natural Killer) Cells for All Participants in Cohorts 1-4
cells/mclPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
Baseline122.0 ± 156.14136.0 ± 38.34174.0 ± 88.43107.0 ± 40.82142.0 ± 48.32
Week 4142.5 ± 136.42103.0 ± 46.6144.0 ± 46.13143.0 ± 45.80181.0 ± 82.05
Week 16130.0 ± 30.41150.0 ± 34.55226.0 ± 90.19138.0 ± 49.69153.0 ± 54.99
Week 20204.0 ± 201.87——181.0 ± 58.45189.0 ± 120.94
Week 24195.0 ± 173.776——135.0 ± 41.35270.0 ± 142.83
SecondaryPharmacodynamic Effect of VIS649 on Circulating CD19 (B Cells) for All Participants in Cohorts 1-4

The effect of VIS649 treatment on the population of circulating CD19 (B Cells) in serum for all participants in cohorts 1-4.

Time frame:
From baseline to Week 24
Reported as:
Median · cells/uL
Pharmacodynamic Effect of VIS649 on Circulating CD19 (B Cells) for All Participants in Cohorts 1-4
cells/uLPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
Baseline165 ± 128.25193.0 ± 23.72244.0 ± 89.67268.0 ± 79.96179.0 ± 49.44
Week 4187.0 ± 73.92206.0 ± 34.69204.0 ± 78.55294.0 ± 129.97202.0 ± 67.12
Week 16166.0 ± 93.65226.0 ± 51.84209.0 ± 98.99359.0 ± 113.22167.0 ± 55.86
Week 20277.5 ± 70.72——320.0 ± 146.34190.0 ± 72.04
Week 24270.5 ± 76.49——267.0 ± 65.38239.0 ± 76.41
SecondaryPharmacodynamic Effect of VIS649 on Circulating CD4 T Cells for All Participants in Cohorts 1-4

The effect of VIS649 treatment on the population of circulating CD4 T cells in serum for all participants in cohorts 1-4.

Time frame:
From baseline to Week 24
Reported as:
Median · cells/uL
Pharmacodynamic Effect of VIS649 on Circulating CD4 T Cells for All Participants in Cohorts 1-4
cells/uLPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
Baseline679.0 ± 178.00592.0 ± 156.93755.0 ± 145.8553.0 ± 288.67698.0 ± 166.09
Week 4601.5 ± 91.92631.0 ± 182.52733.0 ± 194.08592.0 ± 337.55813.0 ± 233.06
Week 16608.0 ± 153.29649.0 ± 198.87718 ± 127.74606.0 ± 347.79799.0 ± 208.09
Week 20895.0 ± 279.84——630.0 ± 300.58738.0 ± 255.19
Week 24917.0 ± 245.42——499.0 ± 196.44992.0 ± 374.77
SecondaryPharmacodynamic Effect of VIS649 on Circulating CD3 T Cells for All Participants in Cohorts 1-4

The effect of VIS649 treatment on the population of circulating CD3 T cells in serum for all participants in cohorts 1-4.

Time frame:
From baseline to Week 24
Reported as:
Median · cells/uL
Pharmacodynamic Effect of VIS649 on Circulating CD3 T Cells for All Participants in Cohorts 1-4
cells/uLPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
Baseline1147.5 ± 313.071118.0 ± 284.461218.0 ± 200.20985.0 ± 365.33991.0 ± 318.12
Week 41074.0 ± 186.09993.0 ± 292.841110.0 ± 358.191018.0 ± 407.51226.0 ± 433.57
Week 161025.0 ± 300.381085.0 ± 220.1781082.0 ± 140.941208.0 ± 437.351270.0 ± 367.31
Week 201565.0 ± 340.67——970.0 ± 387.461139.0 ± 558.77
Week 241644.5 ± 299.56——868.0 ± 207.341259.0 ± 722.50
SecondaryPharmacodynamic Effect of VIS649 on Circulating CD8 T Cells for All Participants in Cohorts 1-4

The effect of VIS649 treatment on the population of circulating CD8 T cells in serum for all participants in cohorts 1-4.

Time frame:
From baseline to Week 24
Reported as:
Median · cells/uL
Pharmacodynamic Effect of VIS649 on Circulating CD8 T Cells for All Participants in Cohorts 1-4
cells/uLPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4
Baseline483.5 ± 145.06442.0 ± 165.29356.0 ± 103.21373.0 ± 108.08327 ± 199.67
Week 4424.0 ± 112.24338.0 ± 135.81373.0 ± 152.41370.0 ± 129.55397.0 ± 246.05
Week 16373.0 ± 166.71471.0 ± 66.20349.0 ± 66.96391.0 ± 137.52461.0 ± 210.56
Week 20623.0 ± 110.15——362.0 ± 145.02416.0 ± 359.67
Week 24702.0 ± 86.56——322.0 ± 66.27342.0 ± 443.94
SecondarySummary of Anti -VIS649 Anti-drug Antibodies (ADA)

Summary of Anti -VIS649 anti-drug antibodies (ADA) by treatment group, all participants

Time frame:
Baseline to Day 112
Reported as:
Count of participants · Participants
Summary of Anti -VIS649 Anti-drug Antibodies (ADA)
ParticipantsPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + Vaccine
Baseline — Negative87777510
Baseline — Positive0000000
Week 4 — Negative8777758
Week 4 — Positive0000001
Week 8 — Negative8657658
Week 8 — Positive0010001
Week 16 — Negative8735357
Week 16 — Positive0022402
SecondarySummary of Anti -VIS649 Antibody (ADA) Titer by Treatment

Summary of Anti -VIS649 antibody (ADA) titer by treatment, all participants with ADA positive results

Time frame:
Baseline to Day 112
Reported as:
Median · titer
Summary of Anti -VIS649 Antibody (ADA) Titer by Treatment
titerPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + Vaccine
Week 4——————1.0
Week 8——0.0———0.0
Week 16——32.0 ± 45.2518.0 ± 19.806.0 ± 6.83—2.0 ± 2.83
SecondaryCmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants by Anti-VIS649 Status

The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 status (positive or negative).

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · μg/mL
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants by Anti-VIS649 Status
μg/mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
Negative12.600 ± 2.22248.660 ± 12.040134.100 ± 23.730259.000 ± 65.110136.300 ± 18.420
Positive—48.450 ± 15.340140.500 ± 13.440300.300 ± 29.900117.700 ± 21.140
SecondaryTmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants by Anti-VIS649 Status

The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 status (positive or negative).

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Median · hours
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants by Anti-VIS649 Status
hoursVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
Negative1.136 (1.12 to 3.11)1.434 (1.15 to 3.09)3.038 (1.14 to 3.16)3.064 (1.11 to 9.11)3.049 (1.14 to 25.11)
Positive—3.058 (3.05 to 3.07)2.089 (1.13 to 3.05)1.142 (1.12 to 3.09)3.055 (3.05 to 3.07)
SecondaryThe Pharmacokinetic Exposure Profiles of VIS649 in Serum Samples, All Participants by Anti-VIS649 Antibody Status.

Summary of the pharmacokinetic profiles of VIS649 exposure in serum for all participants based on their anti-VIS649 antibody status (negative/positive). AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · h*μg/mL
The Pharmacokinetic Exposure Profiles of VIS649 in Serum Samples, All Participants by Anti-VIS649 Antibody Status.
h*μg/mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
AUC 0-112 days--ADA Negative participants1118 ± 209.40012270 ± 387671440 ± 19090177700 ± 3133056390 ± 17870
AUC 0-112 days--ADA Positive participants—10200 ± 180582120 ± 21210175300 ± 2654061450 ± 23170
AUC 0-last--ADA negative participants885.2 ± 146.20010750 ± 327769700 ± 20050145100 ± 1695051550 ± 17860
AUC 0-last--ADA positive participants—9922 ± 186380410 ± 21040151800 ± 1981058500 ± 21880
AUC 0-inf--ADA negative participants1118 ± 209.50012260 ± 387871340 ± 19120194300 ± 4928056450 ± 17930
AUC 0-inf--ADA positive participants—10200 ± 180681980 ± 21350182100 ± 2976061320 ± 23060
SecondaryT1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants by Anti-VIS649 Antibody Status.

The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (negative/positive).

Time frame:
0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Reported as:
Mean · hours
T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants by Anti-VIS649 Antibody Status.
hoursVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
T1/2 ADA Negative participants60.720 ± 4.346192.600 ± 29.040224.600 ± 85.810738.4 ± 281.800335.300 ± 96.780
T1/2 ADA Positive participants—131.900 ± 14.750246.600 ± 68.520618.8 ± 59.450358.200 ± 95.520
SecondaryCL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. All Participants by Anti-VIS649 Antibody Status.

The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (positive or negative)..

Time frame:
112 days
Reported as:
Mean · mL/h
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. All Participants by Anti-VIS649 Antibody Status.
mL/hVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
CL--ADA negative participants31.460 ± 4.54410.870 ± 2.0236.536 ± 2.2034.019 ± 1.5009.272 ± 4.765
CL--ADA positive participants—13.750 ± 3.1535.097 ± 2.8904.875 ± 1.3647.445 ± 2.324
SecondaryVd: The Volume of Distribution of VIS649 in Serum Samples. All Participants by Anti-VIS649 Antibody Status (Positive or Negative)

The calculated volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (positive or negative).

Time frame:
112 days
Reported as:
Mean · mL
Vd: The Volume of Distribution of VIS649 in Serum Samples. All Participants by Anti-VIS649 Antibody Status (Positive or Negative)
mLVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4VIS649 Cohort 5 + Vaccine
Vd--ADA negative2747 ± 351.6002961 ± 287.2002274 ± 14743894 ± 548.84026 ± 983.8
Vd--ADA positive—2584 ± 307.5001956 ± 15324292 ± 962.63641 ± 171.100

Adverse events

Collected over From Day -1 to Day 112. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pooled Placebo0/8 (0%)0/8 (0%)4/8 (50%)
VIS649 Cohort 10/7 (0%)0/7 (0%)2/7 (28.6%)
VIS649 Cohort 20/7 (0%)0/7 (0%)3/7 (42.9%)
VIS649 Cohort 30/7 (0%)0/7 (0%)3/7 (42.9%)
VIS649 Cohort 40/7 (0%)0/7 (0%)3/7 (42.9%)
Placebo Cohort 5 + Vaccine0/5 (0%)0/5 (0%)3/5 (60%)
VIS649 Cohort 5 + Vaccine0/10 (0%)0/10 (0%)4/10 (40%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + Vaccine
Diarrhoea, Food poisoning, Constipation, or VomitingGastrointestinal disorders1/80/71/71/72/72/50/10
Infections and infestationsInfections and infestations1/81/71/71/70/72/51/10
Dizziness, Headache, Head discomfort, Migraine, Somnolence, Syncope, or Taste disorderNervous system disorders1/81/72/72/71/70/50/10
General disorders and administration site conditionsGeneral disorders2/80/71/71/71/71/51/10
Rash papularSkin and subcutaneous tissue disorders0/80/70/70/71/71/50/10
Back pain or MyalgiaMusculoskeletal and connective tissue disorders0/80/71/71/70/70/50/10
BlepharitisEye disorders0/80/70/70/71/70/50/10
Decreased appetiteMetabolism and nutrition disorders0/80/70/70/71/70/50/10
Menopausal symptomsReproductive system and breast disorders0/80/71/70/70/70/50/10
SunburnInjury, poisoning and procedural complications1/80/70/70/70/70/51/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + VaccineTotal
Mean32.6 ± 9.2429.4 ± 6.7040.4 ± 11.7041.0 ± 9.6340.9 ± 11.8733.4 ± 8.4430.9 ± 7.2835.3 ± 9.99
Sex: Female, Male
Sex: Female, Male(Participants)Pooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + VaccineTotal
Female355543429
Male522232622
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + VaccineTotal
American Indian or Alaska Native00000000
Asian433330016
Native Hawaiian or Other Pacific Islander00000000
Black or African American323133722
White121312313
More than one race00000000
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(participants)Pooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + VaccineTotal
United States8777751051
Height (cm)
Height (cm)(cm)Pooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + VaccineTotal
Mean170.9 ± 8.22165.4 ± 10.11165.3 ± 11.91166.4 ± 7.93167.1 ± 13.04167.8 ± 10.33174.9 ± 11.82168.7 ± 10.64
Weight (kg)
Weight (kg)(Kg)Pooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + VaccineTotal
Mean73.53 ± 15.37869.64 ± 11.56366.3 ± 16.23670.03 ± 11.51767.24 ± 12.69971.36 ± 4.22574.33 ± 10.62470.60 ± 12.097
Body Mass Index
Body Mass Index(kg/m2)Pooled PlaceboVIS649 Cohort 1VIS649 Cohort 2VIS649 Cohort 3VIS649 Cohort 4Placebo Cohort 5 + VaccineVIS649 Cohort 5 + VaccineTotal
Mean25.10 ± 4.27525.39 ± 2.81223.96 ± 3.62524.86 ± 4.15624.00 ± 2.86425.52 ± 2.90624.52 ± 2.01124.67 ± 3.145
08

Study locations

1 site
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
09

References and documents

Publications

  • McCafferty K, Barratt J, Suzuki Y, Liew A, Rizk DV, Chacko B, Kooienga L, Lafayette R, Wong MG, Pasetti MF, Shriver MC, Follman K, Moc Willeford C, Sahay M, Honig G, Andrews L, Olinski LE, Mathur M, Oldach D. Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial. Clin J Am Soc Nephrol. 2026 Jun 11. doi: 10.2215/CJN.0000001089. Online ahead of print. PubMed 42275148 ↗
  • Mathur M, Barratt J, Suzuki Y, Engler F, Pasetti MF, Yarbrough J, Sloan S, Oldach D. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022 Feb 8;7(5):993-1003. doi: 10.1016/j.ekir.2022.01.1073. eCollection 2022 May. PubMed 35570983 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2019, 10 months.

Results were first posted in Mar 2025, 5 years 7 months after primary completion.

Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 10 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2018
First posted
Oct 25, 2018
StartActual
Oct 9, 2018
Primary completionActual
Aug 10, 2019
CompletionActual
Aug 10, 2019
Results first posted
Mar 20, 2025
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03719443
Responsible party
Sponsor
First posted
Oct 25, 2018
Start date
Oct 9, 2018
Primary completion
Aug 10, 2019
Completion
Aug 10, 2019
Results posted
Mar 20, 2025
Last update
May 1, 2026

Study contacts

Esther Yoon, MD
principal investigator · Parexel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sibeprenlimab

Start the discussion